HUTCHMED (China) Ltd (HCM) Form 6-K — May 22, 2026
HUTCHMED (China) Ltd announced that pivotal Phase II clinical data for savolitinib in MET-amplified gastric cancer will be presented in a rapid oral session at the 2026 ASCO Annual Meeting. The study met its primary endpoint of objective response rate (ORR) with an IRC-assessed rate of 32.3%, exceeding the pre-specified efficacy threshold. The data supports a New Drug Application (NDA) for savolitinib in China, which was accepted by the NMPA and granted priority review in December 2025. Secondary endpoints included a disease control rate of 63.1% and a median progression-free survival of 4.0 months.
Key figures
- Savolitinib dcr
- 63.1%
- Savolitinib orr
- 32.3%
- Savolitinib median dor months
- 9.7
- Savolitinib median pfs months
- 4
- Savolitinib median ttr months
- 1.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.